Literature DB >> 23182291

[Severe hepatitis in a patient with adult-onset Still's disease treated with anakinra].

A Diallo1, A Mekinian, L Boukari, H Mouas, M Zamy, P Nahon, M Gérin, O Fain.   

Abstract

INTRODUCTION: Adult-onset Still's disease is characterized by non-specific polymorphic features. The efficacy of anakinra, an IL-1 receptor antagonist, has been shown in several studies. This medication is well-tolerated, and only one case of severe hepatitis has been previously reported. CASE REPORT: A 22-year-old woman presented with fever, rash, arthritis, and pericarditis, associated with systemic inflammatory response syndrome and elevated ferritin serum level with low glycosylated ferritin. Adult-onset Still's disease was diagnosed, but treatment with steroids did not achieve remission. The patient was then treated with anakinra, which resulted in spectacular improvement, but 3 weeks after the initiation of the treatment she experienced severe hepatitis that resolved after the discontinuation of anakinra.
CONCLUSION: Hepatitis is a rare side effect of anakinra and the monitoring of liver tests should be recommended during anakinra therapy.
Copyright © 2012 Société nationale française de médecine interne (SNFMI). Published by Elsevier SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23182291     DOI: 10.1016/j.revmed.2012.10.372

Source DB:  PubMed          Journal:  Rev Med Interne        ISSN: 0248-8663            Impact factor:   0.728


  4 in total

1.  Severe hyperferritinemia--a clue for severe hepatitis in a patient with adult-onset Still's disease.

Authors:  Rema Bishara; Yolanda Braun-Moscovici; Amir Dagan; Kohava Toledano; Tarek Saadi; Edmond Sabo; Alexandra Balbir-Gurman
Journal:  Clin Rheumatol       Date:  2014-11-22       Impact factor: 3.650

2.  Anakinra Hepatotoxicity in a Patient With Adult-Onset Still's Disease.

Authors:  Osman Ahmed; Mayur Brahmania; Majid Alsahafi; Saad Alkhowaiter; Sig Erb
Journal:  ACG Case Rep J       Date:  2015-04-10

Review 3.  Biologic and Checkpoint Inhibitor-Induced Liver Injury: A Systematic Literature Review.

Authors:  Parth Shah; Vinay Sundaram; Einar Björnsson
Journal:  Hepatol Commun       Date:  2020-01-02

4.  Management of adult-onset Still's disease with interleukin-1 inhibitors: evidence- and consensus-based statements by a panel of Italian experts.

Authors:  Serena Colafrancesco; Maria Manara; Alessandra Bortoluzzi; Teodora Serban; Gerolamo Bianchi; Luca Cantarini; Francesco Ciccia; Lorenzo Dagna; Marcello Govoni; Carlomaurizio Montecucco; Roberta Priori; Angelo Ravelli; Paolo Sfriso; Luigi Sinigaglia
Journal:  Arthritis Res Ther       Date:  2019-12-11       Impact factor: 5.156

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.